Corrigendum re “Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study” (European Urology (2012) 62(5) (797–802), (S0302283812006082) (10.1016/j.eururo.2012.05.032))

It has been brought to our attention that for the secondary outcome of tumour response, we reported an incorrect p value of 0.04 for a χ2 test comparing the groups. A careful reanalysis of all our results revealed that the p value is in fact 0.054 for this secondary outcome. However, we believe that given the low number of patients included in the study, a p value 0.054 instead of 0.04, which demonstrates borderline significance, does not invalidate the main study results. Conflicts of interest The authors have nothing to disclose.